**Name of Journal:** *World Journal of Obstetrics and Gynecology*

**Manuscript NO:** 74576

**Manuscript Type:** CASE REPORT

**Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report**

Spinelli C *et al*. Follicular thyroid cancer during pregnancy

Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli, Elisabetta Micelli

**Claudio Spinelli, Beatrice Sanna, Marco Ghionzoli,** Division of Pediatric and Adolescent Surgery, Department of Surgical, Medical, Molecular Pathology and of the Critic Area, University of Pisa, Pisa 56100, Italy

**Elisabetta Micelli,** Division of Gynecology and Obstetrics, University of Pisa, Pisa 56100, Italy

**Author contributions:** Spinelli C, Sanna B and Micelli E participated in conception and design, drafting the article and acquisition of data; Sanna B and Ghionzoli M participated in acquisition of data and analysis and interpretation of data; All of the co-authors interpreted the data, participated in the completion of the article, and approved the final version of the article.

**Corresponding author: Marco Ghionzoli, MD, PhD, Attending Doctor,** Division of Pediatric and Adolescent Surgery, Department of Surgical, Medical, Molecular Pathology and of the Critic Area, University of Pisa, Via Roma 67, Pisa 56100, Italy. marco.ghionzoli@meyer.it

**Received:** December 28, 2021

**Revised:** March 22, 2022

**Accepted: May 28, 2022**

**Published online:**

**Abstract**

BACKGROUND

Hormones could play a role in the evolution of follicular thyroid cancer (FTC) for which we discuss an unusual presentation of FTC occurring during pregnancy.

CASE SUMMARY

A pregnant woman was admitted with FTC metastasis resulting in a gluteal mass. Preoperative abdominal computed tomography revealed liver metastasis for which the patient underwent total thyroidectomy and liver resection, oral radioiodine therapy and radiotherapy, followed by embolization of the pelvic mass. The patient died of cerebral hemorrhage 16 mo after the initial diagnosis.

CONCLUSION

Human chorionic gonadotropin and estrogen stimulation might have a role in cancer growth, especially during pregnancy. FTC management aims to stop disease progression and overcome hormonal imbalances after thyroidectomy thus reducing fetal complications. It is still under debate whether it is possible to combine optimal timing for treatment to ensure the best possible outcome with reduction of fetal complications and risk of cancer growth.

**Key Words:** Gluteal pain; Follicular thyroid cancer; Metastases; Pregnancy; Unusual presentation; Case report

Spinelli C, Sanna B, Ghionzoli M, Micelli E. Therapeutic challenges in metastatic follicular thyroid cancer occurring in pregnancy: A case report. *World J Obstet Gynecol* 2022; In press

**Core Tip:** We discuss an uncommon presentation of follicular thyroid cancer occurring during pregnancy. Beta human chorionic gonadotropin and estrogens could take part in the progression of thyroid tumors.

**INTRODUCTION**

Thyroid cancer is reported as the second most common type of cancer diagnosed during pregnancy, followed by breast cancer[1]. Although the effects of pregnancy on the behavior of this tumor have already been widely discussed, the number of reported cases is too small to draw any conclusions. We assume that beta human chorionic gonadotropin (β-hCG) and estrogens could play a role in the progression and prognosis of the tumor. To date, few reports of follicular thyroid cancer (FTC) causing bone metastases[2-5] (skull[6], mandible[7], maxilla[8], spine[9] and orbit[10]) are described, whereas no cases of gluteus metastases have been reported.

Its management during pregnancy remains challenging. It is crucial to stop the disease progression as well as to overcome the hormonal imbalances after thyroidectomy to avoid fetal complications as a consequence of maternal hypothyroidism[11,12]. The actual standard of care for patients diagnosed with thyroid cancer is a total or near-total thyroidectomy either in the second trimester or after delivery. This treatment is followed by radioactive iodine administration (RAI), contraindicated during pregnancy, as an additional treatment for differentiated thyroid cancer (DTC)[13]. The RAI treatment, with the subsequent total loss of thyroid function and follow-up scintigraphy, is usually postponed to the neonatal period in order to avoid fetal congenital hypothyroidism. A deferred postpartum treatment does not seem to alter the prognosis of thyroid cancer. To our knowledge, patients who undergo postponed surgery should receive thyroid hormone suppression treatment (L-thyroxin) until the definitive surgical treatment[14,15]. It remains controversial to establish whether it is beneficial to postpone the treatment schedule in order to avoid early delivery or if a timely treatment should be mandatory.

**CASE PRESENTATION**

***Chief complaints***

Herein we report on an otherwise healthy pregnant woman who came to our attention with hip pain associated with a mass resulting as an FTC metastasis.

***History of present illness***

A 43-year-old pregnant woman, with no other comorbidities, was admitted at her 30th wk of gestation at our Institution for progressive pain in the right gluteal/iliac region.

***History of past illness***

Past history showed no smoking or alcohol consumption habits, neither allergies nor history of hypertension, diabetes mellitus, bronchial asthma, tuberculosis or neck swelling.

***Personal and family history***

No hormonal fertility treatment had ever been performed on the patient who conceived naturally, carrying her first healthy pregnancy.

***Physical examination***

Physical examination showed a palpable lump of the right gluteus.

***Laboratory examinations***

Blood tests revealed: thyroglobulin ≥ 10000 (normal value: 3-40 ng/mL), α-FP = 93.4 (normal value: < 6.0 ng/mL), β-hCG = 896 (post-partum) and calcitonin = 15.2 pg/mL (normal value: < 16 pg/mL).

***Imaging examinations***

The abdominal and pelvic computed tomography (CT) scan and magnetic resonance imaging (Figure 1) revealed a solid polylobate mass of 7.3 cm × 7.9 cm × 11 cm with osteolytic involvement of the right portion of the sacrum, of the sacroiliac synchondrosis and of the contiguous iliac bone, extending to the soft tissues of the gluteus. The fetus was delivered *via* cesarean section at 35 wk of gestation without any issue reported concerning his wellbeing. After delivery, a total hysterectomy with bilateral adnexectomy and biopsies of the gluteal mass were performed.

Preoperative ultrasonography and CT scan showed a right thyroid lobe nodule with maximum axial diameter of 12 mm. No enlarged laterocervical, mediastinal, hilar and axillary lymph nodes were found whilst a 5.5 cm solid mass was detected within the liver parenchyma (4th and 8th segments).

**FINAL DIAGNOSIS**

The histopathological examination confirmed differentiated epithelial follicular neoplasm by morphology and immunohistochemistry (CK+, TTF1+, thyroglobulin +) compatible with FTC metastasis (stage IV). To our knowledge, there have been no previous case reports of FTC in young pregnant patients presenting with gluteal and liver metastasis with no sign of thyroid symptoms.

**TREATMENT**

Given these findings and the age of the patient, we opted for a total thyroidectomy and liver resection with cholecystectomy (Figure 2).

Because of the complex nature of the disease, 2 mo after the last surgery the patient underwent oral RAI. The first cycle (131-iodine, 3700 MBq dose) did not show the expected improvement. Therefore, it was decided to perform a second round of radioiodine treatment (131-iodine, 5550 MBq dose). Due to the non-resectability of the pelvic mass, 20 d after the RAI treatment, the patient underwent palliative radiotherapy with an external beam on D10 with a total dose of 2000 cGy in 5 fractions. Following radiotherapy, the right gluteal mass displayed an initial reduction with pain relief although after a few months relapsed. Therefore, it was considered to perform a vascular embolization leading to subtotal devascularization of the tumor.

**OUTCOME AND FOLLOW-UP**

A positron emission tomography (PET)/CT scan performed about 2 mo later showed the failure of this last procedure. Eventually, the patient died of cerebral hemorrhage 16 mo after the initial diagnosis.

**DISCUSSION**

Amongst all DTCs detected in women during their fertile age, about 10% are diagnosed during pregnancy or shortly after[16]. Female prevalence and increasingly age-specific incidence in women during the child-bearing period suggests a possible role of sexual hormones in the development of thyroid cancer, especially in cases of DTCs (papillary thyroid carcinoma and FTC). However, there is an ongoing debate about the role of pregnancy hormones with regard to the prognosis of DTC[17,18]. The pathophysiological framework of an increased risk of developing thyroid cancer and its progression in pregnant patients is still under debate. β-hCG and estrogen stimulation, increased vascularization and the absence of immune surveillance against cancer may be involved[19]. Hormonal stimulation during pregnancy might escalate the progression of thyroid cancer, suggesting that a more aggressive approach might be required in affected women[20-22]. Thyroid gland size normally increases by 30% during the first and third trimesters of pregnancy, and thyrotropin (TSH) levels fluctuate during pregnancy as they decrease during the first trimester to return to normal range during the following months[23].

β-hCG belongs to the subfamily of glycoprotein hormones, displaying a structural accordance both with TSH and its receptors. This similarity suggests the basis for β-hCG cross-reactivity with the TSH receptor[24]. β-hCG has a stimulating effect on the thyroid gland as it can be noted in gestational trophoblastic diseases that present with high levels of β-hCG and hyperthyroidism. Furthermore, β-hCG is the strongest stimulator of thyroid growth during the first trimester of pregnancy[25]. Therefore, in susceptible thyroid follicular cells (*e.g.*, when *BRAF* and *RAS* mutations or *RET*/*PTC* and *PAX8-PPAR-γ* rearrangements occur), an excessive β-hCG stimulation may lead to rapid cancer progression[26].

Estrogen levels exert their effects through more complicated mechanisms. They have an indirect effect through increasing the serum thyroxine that binds globulin. A manifestation of their direct effect is estrogen receptor (ER) presentation on thyroid gland cells[27]. ERα and ERβ are intracellular nuclear receptors that exist in normal and neoplastic thyroid cells. When estradiol binds to ERα it enhances cell proliferation. On the contrary, ERβ inhibits these effects and leads to apoptosis[28,29]. Recent studies compared expression of ERα and ERβ in normal thyroid cells and malignant thyroid cells, revealing different levels of expression of ERα and a decreased ERβ activity in the latter[30,31].

The musculoskeletal system represents the most common localization for FTC metastases, which can develop in areas of high blood flow, like the red marrow of the axial skeleton, including the vertebrae (42%-52%), femur (9%-20%), skull (2%-16%) and pelvis (5%-13%)[32]. FTC usually presents itself as a single nodule, which can be either well defined or extensively infiltrating. Lymph node involvement is extremely rare[33]. Magnetic resonance imaging, CT, PET and scintigraphy could complete the diagnostic work-up to reveal metastases[34].

Surgery is the gold standard treatment for FTC. In all patients it is mandatory to balance risks against advantages of thyroid lobectomy with subsequent completion *vs* initial total thyroidectomy[33,35]. Thyroid cancer during pregnancy poses many challenges due to the need to carefully focus on both optimal timing for recommended treatments and the risks of cancer growth. The Endocrine Society recommends thyroidectomy following delivery for pregnancy-related DTC in patients showing no evidence of advanced disease or rapid progression. Meanwhile it is advisable to perform thyroidectomy during the second trimester of pregnancy in complicated cases. Lymph node dissection is not indicated in the absence of palpable lymph nodes[35-39]. Suppressive treatment with levothyroxine therapy is required after surgical treatment. Its aim is to keep TSH levels below 0.1-1 mU/L, with monthly monitoring of TSH and T4 levels.

However, if surgery is performed during pregnancy, levothyroxine therapy should promptly begin after surgery[39,40]. The post-surgical radio-ablation of the residual thyroid tissue facilitates the use of thyroglobulin detection and radioiodine scanning for long-term follow-up. Consequently, for patients at risk of recurrence and for those with known distant metastatic disease, 131I ablation may represent a valid therapeutic strategy[20]. Not all patients benefit from radioiodine therapy, and this treatment is contraindicated in pregnant and in breastfeeding women[30].

The presence of molecular pathway alterations in different DTC (*RET*/*PTC* rearrangements, *RET* mutations, *BRAF* mutations, *RAS* mutations and VEGFR-2 expression) has allowed the development of new selective drugs. Tyrosine kinase inhibitors are small organic compounds inhibiting tyrosine kinase autophosphorylation and activation; most of them are multikinase inhibitors. Tyrosine kinase inhibitors act on the aforementioned molecular pathways involved in growth, angiogenesis and local and distant spread of DTC and are emerging as a new approach for aggressive thyroid cancer[41].

**CONCLUSION**

β-hCG and estrogen stimulation might have a role in cancer growth, especially during pregnancy. FTC management aims to stop disease progression and overcome hormonal imbalances after thyroidectomy thus reducing fetal complications. It is still under debate whether it is possible to combine optimal timing for treatment to ensure the best possible outcome with reduction of fetal complications and risk of cancer growth.

**REFERENCES**

1 **Smith LH**, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. *Am J Obstet Gynecol* 2003; **189**: 1128-1135 [PMID: 14586366 DOI: 10.1067/s0002-9378(03)00537-4]

2 **Budak A**, Gulhan I, Aldemir OS, Ileri A, Tekin E, Ozeren M. Lack of influence of pregnancy on the prognosis of survivors of thyroid cancer. *Asian Pac J Cancer Prev* 2013; **14**: 6941-6943 [PMID: 24377629 DOI: 10.7314/apjcp.2013.14.11.6941]

3 **Schlumberger M**, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 1986; **63**: 960-967 [PMID: 3745409 DOI: 10.1210/jcem-63-4-960]

4 **Shaha AR**, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. *Am J Surg* 1997; **174**: 474-476 [PMID: 9374217 DOI: 10.1016/s0002-9610(97)00158-x]

5 **Kim H**, Kim HI, Kim SW, Jung J, Jeon MJ, Kim WG, Kim TY, Kim HK, Kang HC, Han JM, Cho YY, Kim TH, Chung JH. Prognosis of Differentiated Thyroid Carcinoma with Initial Distant Metastasis: A Multicenter Study in Korea. *Endocrinol Metab (Seoul)* 2018; **33**: 287-295 [PMID: 29947184 DOI: 10.3803/EnM.2018.33.2.287]

6 **Ozdemir N**, Senoğlu M, Acar UD, Canda MS. Skull metastasis of follicular thyroid carcinoma. *Acta Neurochir (Wien)* 2004; **146**: 1155-8; discussion 1158 [PMID: 15744853 DOI: 10.1007/s00701-004-0290-8]

7 **Anil S**, Lal PM, Gill DS, Beena VT. Metastasis of thyroid carcinoma to the mandible. Case report. *Aust Dent J* 1999; **44**: 56-57 [PMID: 10217022 DOI: 10.1111/j.1834-7819.1999.tb00537.x]

8 **Hefer T**, Manor R, Zvi Joachims H, Groisman GM, Peled M, Gov-Ari E, Laufer D. Metastatic follicular thyroid carcinoma to the maxilla. *J Laryngol Otol* 1998; **112**: 69-72 [PMID: 9538450 DOI: 10.1017/s0022215100139921]

9 **Scarrow AM**, Colina JL, Levy EI, Welch WC. Thyroid carcinoma with isolated spinal metastasis: case history and review of the literature. *Clin Neurol Neurosurg* 1999; **101**: 245-248 [PMID: 10622453 DOI: 10.1016/s0303-8467(99)00040-2]

10 **Daumerie C**, De Potter P, Godfraind C, Rahier J, Jamar F, Squifflet JP. Orbital metastasis as primary manifestation of thyroid carcinoma. *Thyroid* 2000; **10**: 189-192 [PMID: 10718558 DOI: 10.1089/thy.2000.10.189]

11 **Mazzaferri EL**. Approach to the pregnant patient with thyroid cancer. *J Clin Endocrinol Metab* 2011; **96**: 265-272 [PMID: 21296990 DOI: 10.1210/jc.2010-1624]

12 **Galofré JC**, Riesco-Eizaguirre G, Alvarez-Escolá C; Grupo de Trabajo de Cáncer de Tiroides de la Sociedad Española de Endocrinología y Nutrición. Clinical guidelines for management of thyroid nodule and cancer during pregnancy. *Endocrinol Nutr* 2014; **61**: 130-138 [PMID: 24176541 DOI: 10.1016/j.endonu.2013.08.003]

13 **Khaled H**, Al Lahloubi N, Rashad N. A review on thyroid cancer during pregnancy: Multitasking is required. *J Adv Res* 2016; **7**: 565-570 [PMID: 27408758 DOI: 10.1016/j.jare.2016.02.007]

14 **Gibelli B**, Zamperini P, Proh M, Giugliano G. Management and follow-up of thyroid cancer in pregnant women. *Acta Otorhinolaryngol Ital* 2011; **31**: 358-365 [PMID: 22323846]

15 **Yu SS**, Bischoff LA. Thyroid Cancer in Pregnancy. *Semin Reprod Med* 2016; **34**: 351-355 [PMID: 27741551 DOI: 10.1055/s-0036-1593484]

16 **Turner HE**, Harris AL, Melmed S, Wass JA. Angiogenesis in endocrine tumors. *Endocr Rev* 2003; **24**: 600-632 [PMID: 14570746 DOI: 10.1210/er.2002-0008]

17 **Kung AW**, Chau MT, Lao TT, Tam SC, Low LC. The effect of pregnancy on thyroid nodule formation. *J Clin Endocrinol Metab* 2002; **87**: 1010-1014 [PMID: 11889153 DOI: 10.1210/jcem.87.3.8285]

18 **Sahin SB**, Ogullar S, Ural UM, Ilkkilic K, Metin Y, Ayaz T. Alterations of thyroid volume and nodular size during and after pregnancy in a severe iodine-deficient area. *Clin Endocrinol (Oxf)* 2014; **81**: 762-768 [PMID: 24811142 DOI: 10.1111/cen.12490]

19 **Alves GV**, Santin AP, Furlanetto TW. Prognosis of thyroid cancer related to pregnancy: a systematic review. *J Thyroid Res* 2011; **2011**: 691719 [PMID: 21811666 DOI: 10.4061/2011/691719]

20 **Longo DA,** Anthony S. Fauci AS. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, 2012

21 **Huang TC**, Cheng YK, Chen TW, Hsu YC, Liu EW, Chen HH. A 'silent' skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman. *Endocrinol Diabetes Metab Case Rep* 2017; **2017** [PMID: 28203373 DOI: 10.1530/EDM-16-0100]

22 **Yoshimura M**, Hershman JM. Thyrotropic action of human chorionic gonadotropin. *Thyroid* 1995; **5**: 425-434 [PMID: 8563483 DOI: 10.1089/thy.1995.5.425]

23 ACOG Practice Bulletin No. 144: Multifetal gestations: twin, triplet, and higher-order multifetal pregnancies. *Obstet Gynecol* 2014; **123**: 1118-1132 [PMID: 24785876 DOI: 10.1097/01.AOG.0000446856.51061.3e]

24 **Dean DS**, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. *Cancer Control* 2000; **7**: 229-239 [PMID: 10832109 DOI: 10.1177/107327480000700302]

25 **Walkington L**, Webster J, Hancock BW, Everard J, Coleman RE. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. *Br J Cancer* 2011; **104**: 1665-1669 [PMID: 21522146 DOI: 10.1038/bjc.2011.139]

26 **Tafani M**, De Santis E, Coppola L, Perrone GA, Carnevale I, Russo A, Pucci B, Carpi A, Bizzarri M, Russo MA. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression. *Biomed Pharmacother* 2014; **68**: 1-5 [PMID: 24286852 DOI: 10.1016/j.biopha.2013.10.013]

27 **Coelho RG**, Fortunato RS, Carvalho DP. Metabolic Reprogramming in Thyroid Carcinoma. *Front Oncol* 2018; **8**: 82 [PMID: 29629339 DOI: 10.3389/fonc.2018.00082]

28 **Gabriela V,** Arciuch A, Di Cristofano A. Estrogen signaling and thyrocyte proliferation. In: Ward L. Thyroid and parathyroid diseases-new insights into some old and some new issues. London: IntechOpen, 2012

29 **Huang Y**, Dong W, Li J, Zhang H, Shan Z, Teng W. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma. *BMC Cancer* 2014; **14**: 383 [PMID: 24884830 DOI: 10.1186/1471-2407-14-383]

30 **Gharib H**, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, Paschke R, Valcavi R, Vitti P; AACE/ACE/AME Task Force on Thyroid Nodules. American Association Of Clinical Endocrinologists, American College Of Endocrinology, And Associazione Medici Endocrinologi Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules--2016 Update. *Endocr Pract* 2016; **22**: 622-639 [PMID: 27167915 DOI: 10.4158/EP161208.GL]

31 **Zahid M**, Goldner W, Beseler CL, Rogan EG, Cavalieri EL. Unbalanced estrogen metabolism in thyroid cancer. *Int J Cancer* 2013; **133**: 2642-2649 [PMID: 23686454 DOI: 10.1002/ijc.28275]

32 **Mizoshiri N**, Shirai T, Terauchi R, Tsuchida S, Mori Y, Saito M, Ueshima K, Kubo T. Metastasis of differentiated thyroid cancer in the subchondral bone of the femoral head: a case report. *BMC Musculoskelet Disord* 2015; **16**: 286 [PMID: 26452365 DOI: 10.1186/s12891-015-0748-2]

33 **Spinelli C**, Rallo L, Morganti R, Mazzotti V, Inserra A, Cecchetto G, Massimino M, Collini P, Strambi S. Surgical management of follicular thyroid carcinoma in children and adolescents: A study of 30 cases. *J Pediatr Surg* 2019; **54**: 521-526 [PMID: 29935896 DOI: 10.1016/j.jpedsurg.2018.05.017]

34 **Schlumberger MJ**. Papillary and follicular thyroid carcinoma. *N Engl J Med* 1998; **338**: 297-306 [PMID: 9445411 DOI: 10.1056/NEJM199801293380506]

35 **Haugen BR**, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016; **26**: 1-133 [PMID: 26462967 DOI: 10.1089/thy.2015.0020]

36 **Moosa M**, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. *J Clin Endocrinol Metab* 1997; **82**: 2862-2866 [PMID: 9284711 DOI: 10.1210/jcem.82.9.4247]

37 **Modesti C**, Aceto P, Masini L, Lombardi CP, Bellantone R, Sollazzi L. Approach to thyroid carcinoma in pregnancy. *Updates Surg* 2017; **69**: 261-265 [PMID: 28639240 DOI: 10.1007/s13304-017-0476-2]

38 **Vannucchi G**, Perrino M, Rossi S, Colombo C, Vicentini L, Dazzi D, Beck-Peccoz P, Fugazzola L. Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. *Eur J Endocrinol* 2010; **162**: 145-151 [PMID: 19828692 DOI: 10.1530/EJE-09-0761]

39 **Papini E**, Negro R, Pinchera A, Guglielmi R, Baroli A, Beck-Peccoz P, Garofalo P, Pisoni MP, Zini M, Elisei R, Chiovato L; Italian Association of Clinical Endocrinologists; Italian Thyroid Association. Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. *J Endocrinol Invest* 2010; **33**: 579-586 [PMID: 20634642 DOI: 10.1007/BF03346652]

40 **Messuti I**, Corvisieri S, Bardesono F, Rapa I, Giorcelli J, Pellerito R, Volante M, Orlandi F. Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. *Eur J Endocrinol* 2014; **170**: 659-666 [PMID: 24510913 DOI: 10.1530/EJE-13-0903]

41 **Ferrari SM**, Fallahi P, Politti U, Materazzi G, Baldini E, Ulisse S, Miccoli P, Antonelli A. Molecular Targeted Therapies of Aggressive Thyroid Cancer. *Front Endocrinol (Lausanne)* 2015; **6**: 176 [PMID: 26635725 DOI: 10.3389/fendo.2015.00176]

**Footnotes**

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interests.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 28, 2021

**First decision:** March 16, 2022

**Article in press:**

**Specialty type:** Obstetrics and gynecology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Chan SM, Taiwan; Tang J, China; Zhang YX, China; Zhao Y, China **A-Editor:** Liu X, China **S-Editor:** Zhang H **L-Editor:** Filipodia CL **P-Editor:** Zhang H

**Figure Legends**

****

**Figure 1 Magnetic resonance imaging of the lower abdomen and pelvis.** Solid formation with osteolytic involvement of the right sacrum, of the sacroiliac synchondrosis and of the contiguous iliac bone was observed.

****

**Figure 2 Follicular thyroid carcinoma.** Fibrous capsule invasion (black arrow). The growth pattern is typically micro and/or macrofollicular. No cytonuclear atypia were present. Original magnification for the panel, × 40.